{{vm.title}}
25{{vm.includesText}}
{{item}}
{{vm.selectText}}
{{ vm.welcomeLabel.trim() }},
{{ vm.userName }}
{{ vm.text }}
{{vm.newUser1}} {{vm.newUser2}} {{vm.newUser3}} {{vm.newUser4}}
{{ vm.unknownUser }}
{{ vm.title }}
{{ vm.title }}
{{ vm.title }}
- {{ vm.siteSelectorList.flyout.cell1.heading }} {{ site.countryLocale }} {{ vm.siteSelectorList.flyout.cell1.global.countryLocale }}
{{ vm.closeTabLabel }}
- {{ vm.flyout.cell2.title }} {{ vm.flyout.cell2.newTabAllow }} {{ vm.flyout.cell2.title }}
- {{ vm.flyout.cell3.title }} {{ vm.flyout.cell3.newTabAllow }} {{ vm.flyout.cell3.title }}
- {{ vm.flyout.cell1.viewAll.label }} {{ vm.flyout.cell1.viewAll.newTabAllow }} {{ vm.flyout.cell1.viewAll.label }}
Deal Capsule - January 2020
Deal Capsule - January 2020
M&A activity will remain moderately strong in both sectors.
Topic of this issue:
2019 deal value grew significantly in both sectors. Life sciences deal value remains at a level several times that of chemicals. Despite a record year for life sciences, M&A activity has been slightly lower in H2 2019. The focus on high-growth segments and therapeutical areas like oncology and on core businesses with innovative drugs have been the key deal drivers in life sciences in 2019.
The chemical sector suffered a decline in M&A deal volume, partly driven by an economic downturn in 2019. Excluding the SABIC deal (USD 69.1 billion), the same holds true for total deal value. Large deals have been mostly related to portfolio optimization.
Online version
Browse directly through the publication
KPMG Deal Capsule Newsletter
© 2020 KPMG AG Wirtschaftsprüfungsgesellschaft, eine Aktiengesellschaft nach deutschem Recht und ein Mitglied der globalen KPMG-Organisation unabhängiger Mitgliedsfirmen, die KPMG International Limited, einer Private English Company Limited by Guarantee, angeschlossen sind. Alle Rechte vorbehalten. Für weitere Einzelheiten über die Struktur der globalen Organisation von KPMG besuchen Sie bitte https://home.kpmg/governance.
